JP2017512838A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512838A5
JP2017512838A5 JP2017502946A JP2017502946A JP2017512838A5 JP 2017512838 A5 JP2017512838 A5 JP 2017512838A5 JP 2017502946 A JP2017502946 A JP 2017502946A JP 2017502946 A JP2017502946 A JP 2017502946A JP 2017512838 A5 JP2017512838 A5 JP 2017512838A5
Authority
JP
Japan
Prior art keywords
antigen
binding fragment
seq
antibody
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017502946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512838A (ja
JP6598844B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/023108 external-priority patent/WO2015148984A2/en
Publication of JP2017512838A publication Critical patent/JP2017512838A/ja
Publication of JP2017512838A5 publication Critical patent/JP2017512838A5/ja
Application granted granted Critical
Publication of JP6598844B2 publication Critical patent/JP6598844B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017502946A 2014-03-27 2015-03-27 ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体 Active JP6598844B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2014074199 2014-03-27
CNPCT/CN2014/074199 2014-03-27
CN2014081797 2014-07-08
CNPCT/CN2014/081797 2014-07-08
PCT/US2015/023108 WO2015148984A2 (en) 2014-03-27 2015-03-27 Antibodies that bind human cannabinoid 1 (cb1) receptor

Publications (3)

Publication Number Publication Date
JP2017512838A JP2017512838A (ja) 2017-05-25
JP2017512838A5 true JP2017512838A5 (enExample) 2018-05-17
JP6598844B2 JP6598844B2 (ja) 2019-10-30

Family

ID=53008849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502946A Active JP6598844B2 (ja) 2014-03-27 2015-03-27 ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体

Country Status (16)

Country Link
US (4) US10308712B2 (enExample)
EP (2) EP3122780B1 (enExample)
JP (1) JP6598844B2 (enExample)
KR (2) KR102553870B1 (enExample)
CN (1) CN106232626B (enExample)
AU (1) AU2015237275B2 (enExample)
CA (1) CA2944049A1 (enExample)
CL (3) CL2016002433A1 (enExample)
ES (1) ES2915101T3 (enExample)
IL (1) IL248006B2 (enExample)
MA (1) MA39708A (enExample)
MX (1) MX2016012403A (enExample)
PE (1) PE20170258A1 (enExample)
RU (1) RU2730674C2 (enExample)
TW (1) TWI694086B (enExample)
WO (1) WO2015148984A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102553870B1 (ko) * 2014-03-27 2023-07-10 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체
MA43049A (fr) * 2015-09-30 2018-08-08 Bird Rock Bio Inc Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1)
JP7235733B2 (ja) 2017-06-05 2023-03-08 ヤンセン バイオテツク，インコーポレーテツド Ｐｄ－１に特異的に結合する抗体、及び使用方法
JP6577691B2 (ja) * 2017-07-13 2019-09-18 協和キリン株式会社 抗ｂｒｉｌ抗体及び該抗体を用いたｂｒｉｌ融合タンパク質の安定化方法
CN108588071A (zh) * 2018-04-25 2018-09-28 和元生物技术（上海）股份有限公司 CRISPR-Cas9靶向敲除人肠癌细胞CNR1基因及其特异性的sgRNA
EA202092593A1 (ru) 2018-04-30 2021-02-12 Такеда Фармасьютикал Компани Лимитед Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение
US20210267959A1 (en) * 2018-07-17 2021-09-02 The Regents Of The University Of California Methods of treating renal disease
US12435131B2 (en) 2019-07-11 2025-10-07 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
US20250243270A1 (en) * 2022-04-04 2025-07-31 Bird Rock Bio Sub, Inc. Prediction and treatment of fast progressing renal disease
JPWO2023234406A1 (enExample) * 2022-06-03 2023-12-07
WO2024022478A1 (zh) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途
WO2024212999A1 (zh) * 2023-04-11 2024-10-17 微境生物医药科技(上海)有限公司 Cbl-b抑制剂
CN118027211A (zh) * 2024-04-11 2024-05-14 上海惠盾因泰生物科技有限公司 一种识别重组egf-crm197疫苗的单克隆抗体及其应用
WO2026024319A1 (en) 2024-07-23 2026-01-29 Bird Rock Bio Sub, Inc. Treatment of obesity and obstructive sleep apnea
CN120647762B (zh) * 2025-06-16 2026-01-23 首都医科大学附属北京友谊医院 一种抗β1-AR-ECII抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466579A (en) 1987-12-28 1995-11-14 Psychemedics Corporation Hair analysis method
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5817766A (en) 1995-04-05 1998-10-06 Roche Diagnostic Systems, Inc. Reagents for a cannabinoid immunoassay
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
HUP0300369A2 (hu) 2000-04-11 2003-06-28 Genentech, Inc. Többértékű antitestek és alkalmazásuk
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
US7754188B2 (en) * 2003-06-30 2010-07-13 Merck Sharp & Dohme Corp. Radiolabeled cannabinoid-1 receptor modulators
US20050095674A1 (en) 2003-07-23 2005-05-05 Lewis Deborah L. Cannabinoid receptor interacting proteins and methods of use
WO2005023232A2 (en) * 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
ITMI20041033A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
CA2609783A1 (en) 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8460362B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
WO2008048648A2 (en) 2006-10-17 2008-04-24 Acadia Pharmaceuticals Inc. Cb1-modulating compounds and their use
EP2152690B1 (en) 2007-05-23 2012-01-11 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
KR101603917B1 (ko) 2008-05-09 2016-03-17 애브비 인코포레이티드 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도
FI20085579A0 (fi) 2008-06-12 2008-06-12 Valtion Teknillinen Kannabiskäytön toteaminen
IT1394400B1 (it) 2009-02-25 2012-06-15 Neuroscienze Pharmaness S C Ar L Composizioni farmaceutiche
JP5812418B2 (ja) 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
US8865163B2 (en) * 2010-07-15 2014-10-21 Oleg I. Epshtein Pharmaceutical compositions and methods of treatment
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
US9441033B2 (en) 2011-02-14 2016-09-13 Randox Laboratories Limited Detection of synthetic cannabinoids
GB201102544D0 (en) 2011-02-14 2011-03-30 Randox Lab Ltd Assay
US9435817B2 (en) 2011-02-14 2016-09-06 Randox Laboratories Limited Detection of synthetic cannabinoids
DK2709631T5 (en) 2011-05-20 2017-10-30 Inserm - Inst Nat De La Santé Et De La Rech Médicale ANTAGONISTS OF CB1 RECEPTOR
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
EP2698383B1 (en) 2012-08-14 2020-11-25 Randox Laboratories Ltd. Detection of synthetic Cannabinoids
AU2014302410B2 (en) 2013-06-26 2019-06-13 Amgen Inc. CB1 receptor antigen-binding proteins and uses thereof
MX2016007369A (es) 2013-12-12 2016-09-08 Stemcentrx Inc Nuevos anticuerpos anti-dpep3 y metodos de uso.
KR102553870B1 (ko) * 2014-03-27 2023-07-10 버드 락 바이오, 인크. 인간 카나비노이드 1(cb1) 수용체 결합 항체

Similar Documents

Publication Publication Date Title
JP2017512838A5 (enExample)
RU2016141919A (ru) Антитела, связывающиеся с человеческим каннабиноидным рецептором 1 (св1)
JP6681433B2 (ja) Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト
AU2018312222B2 (en) Anti-CD47 antibodies and uses thereof
JP7273110B2 (ja) 高親和性抗ｖｅｇｆ抗体
JP2018503380A5 (enExample)
JP2020501531A5 (enExample)
JP2017526370A5 (enExample)
JP2012501669A5 (enExample)
TW202144417A (zh) Ｐｖｒｉｇ結合蛋白及其醫藥用途
JP2008516970A5 (enExample)
JP2012531922A5 (ja) Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位
JP2012501670A5 (enExample)
JP2014500009A5 (enExample)
JP2013502913A5 (enExample)
JP2015530971A5 (enExample)
JP2010526028A5 (enExample)
JP2011207882A5 (enExample)
JP2015533853A5 (enExample)
JP2017505622A5 (enExample)
JP2013538057A5 (enExample)
JP2022507679A (ja) Ｈｅｒ２／ｐｄ１二重特異性抗体
JP2014524733A5 (enExample)
TWI869528B (zh) C5ar1抗體分子及其用途
US20240101675A1 (en) Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof